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Background: Osteoarthritis (OA) is likely to become an increasing burden in the coming decades. Various agents
have been developed to slow the progression of OA, and are collectively known as ‘disease-modifying drugs’ ,
however, there is still little reliable evidence that such agents will be successful. Dehydroepiandrosterone (DHEA), a
sex hormone precursor, has been recently proven as protective agent against OA, but the exact mechanism is still
unkown. In the current study, the effects of weekly intra-articular injections of DHEA in preventing the progression
of existing cartilage degeneration in an OA rabbit model were evaluated. The aim of the current study is to
demonstrate the feature of its disease-modifying efficacy during OA progression.
Methods: Thirty male New Zealand white rabbits were used in this study. An anterior cruciate ligament transection
(ACLT) model was used to create a progressive OA model in twenty rabbits. The animals were treated with DHEA
or a placebo and were necropsied at 9 and 16 weeks. Ten rabbits receiving sham operations served as controls. The
articular cartilage of the medial femoral condyle (MFC), lateral femoral condyle (LFC), medial tibial plateau (MTP)
and lateral tibial plateau (LTP) was evaluated macroscopically and histologically.
Results: In the joints of the sham-operated rabbits, few histological changes were detected on the articular surfaces
of the femoral condyles and tibial plateaus. ACLT obviously induced erosive changes on the cartilage surfaces.
Compared to the placebo group, the macroscopic and Mankin score analyses demonstrated that the DHEA treatment
markedly reduced the cartilage lesions and delayed cartilage degeneration in the four regions of the knee at 9 weeks
after operation (macroscopic score: MFC P = 0.013; LFC P = 0.048; MTP P = 0.045; LTP P = 0.02, Mankin score: MFC
P = 0.012; LFC P = 0.034; MTP P = 0.016; LTP P = 0.002). At 16 weeks, DHEA demonstrated chondroprotective effects on
the lateral compartment of the knee compared to the placebo group, whereas the cartilage degeneration at the medial
compartment of the knee did not differ among the groups (macroscopic score: LFC P = 0.046; LTP = 0.034, Mankin
score: LFC P = 0.005; LTP P = 0.002).
Conclusion: The disease-modifying efficacy of DHEA aganist OA is time-specific and site-dependent. DHEA could be
used as a disease-modifying strategy to limit the progression of OA, especially in the middle stage.
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Osteoarthritis (OA) is a degenerative joint disease that is
generally characterized by progressive cartilage deterior-
ation, sclerosis of the underlying subchondral bone,
osteophyte formation and low-grade synovitis [1]. An
imbalance between the biosynthesis and the degradation
of the matrix components leads to progressive tissue de-
struction, resulting in extensive articular damage [2]. No
disease-modifying treatment for OA exists. The available
treatments for OA predominantly target symptomatic
relief without addressing the fundamental mechanism
underlying OA, which is the destruction of articular car-
tilage [3]. More studies are identifying and characterizing
potential disease-modifying therapeutic agents for OA,
including calcitonin [4], bone morphogenetic protein-7
[5], lubricin [6], trichostatin A [7] and mesenchymal
stem cells [8].
Dehydroepiandrosterone (DHEA) is a 19-carbon steroid
hormone that is classified as an adrenal androgen. DHEA
has been shown to antagonize the catabolic mediators of
cartilage that may exert protective effects in OA, including
suppressing matrix metalloproteinases (MMPs) and indu-
cing cartilage restoration [9]. Our recent research [10]
showed that DHEA demonstrated beneficial effects on
OA by influencing the balance between the aggrecanases
and tissue inhibitors of metalloproteinase-3 (TIMP-3) in
cartilage tissues, suggesting that DHEA might protect ar-
ticular cartilage from degeneration at the molecular level.
In this study, we further explored how this agent exerts its
disease-modifying effect at the histomorphometric level in
an identical animal model of OA.
Increasing evidence demonstrates that there are differ-
ent stages of OA, each with its own distinct pattern of
initiation and progression. One treatment might work in
one stage of the disease and not work in another stage,
which highlights the need for testing cartilage with pos-
sible intervention strategies that target existing morpho-
logical changes that occur during the different stages of
OA. In this study, we explore the effect of DHEA on car-
tilage histology during two OA stages.
To test the reparative efficiency of DHEA, we gener-
ated a rabbit anterior cruciate ligament transection
(ACLT) model of OA, in which the characteristics of the
cartilage degenerative process are highly similar to those
of humans. This study differs from previous research
that used unilateral knee surgery as a model because in
this study, the ACLT surgery was performed bilaterally
to avoid compensatory locomotion in the rabbits. To
investigate the histological modifying effect of DHEA
in more detail, the four compartments of the knee
joint, including the medial femoral condyle (MFC), lat-
eral femoral condyle (LFC), medial tibial plateau (MTP)
and lateral tibial plateau (LTP), in two stages of OA
were analyzed.Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of Zhejiang University. The protocol
was approved by the Committee on the Ethics of Animal
Experiments of Zhejiang University. All surgery was per-
formed under sodium pentobarbital anesthesia, and all
efforts were made to minimize pain and suffering.
Reagents
DHEA (Sigma, Fluka, St. Louis, MO) was used at a con-
centration of 100 μmol/L (dissolved in 0.9 % normal
saline [NS]). This concentration exhibited a protective
effect against articular cartilage loss and demonstrated
no toxic effects on the chondrocytes [9].
Animal groups and treatment
Inclusion criteria: Male New Zealand white rabbits (one
year old) weighed about 2.5-3.5 kg were included. Exclu-
sion criteria: The knee joints of all rabbits were X-rayed
before inclusion. The rabbits with clinical or radio-
graphic evidence of joint disease were excluded. Finally,
thirty rabbits met the inclusion standard and were en-
rolled in the current study for subsequent assessment.
In our previous study, we found that rabbits showed
considerable individual variability in OA progression
after ACLT. To more strictly examine the effect of
DHEA on disease progression, a matched-pair analysis
was used in this study. For the matched pair analyses of
cartilage degradation, 20 rabbits with 40 knees were
used. An additional 10 rabbits with 20 knees underwent
sham surgery and served as the controls.
Twenty rabbits were intravenously anaesthetized with
3 % sodium pentobarbital (1 mL/kg). Both legs were pre-
pared and draped in the usual sterile fashion, and an ap-
proximately 3-cm midline incision was made over the
knee. After dissection through the subcutaneous tissue,
the capsule was incised with a median parapatellar inci-
sion. The patella was dislocated laterally, exposing the
ACL, which was then completely transected. An intraop-
erative Lachman test was performed to verify that in-
stability had been created. An additional 10 rabbits
received sham surgery in which the keen joint capsule
was opened without transecting the ACL after luxation
of patella with the same procedure as OA model. After
surgery, the rabbits were provided appropriate postopera-
tive care and analgesics. Each ACLT-treated rabbit re-
ceived 0.3 mL of DHEA at a concentration of 100 μmol/L
once a week in the left knee, and the right knee was
injected with the same volume of NS as a placebo. The
intra-articular interfering began at week 5. Each sham-
operated rabbit received an identical volume of NS in both
knees beginning at week 5. Half of the animals were
Huang et al. BMC Musculoskeletal Disorders  (2015) 16:178 Page 3 of 10randomly sacrificed 9 weeks after surgery. The remaining
animals were sacrificed 16 weeks after surgery. All knees
were harvested for the analyses. According to the above
treatment strategy, all harvested knees were divided into
the following six groups: 1) sham-operated knees harvested
9 weeks after surgery (Sham, 9 w), 2) sham-operated knees
harvested 16 weeks after surgery (Sham, 16 w), 3) OA
knees with normal saline treatment 9 weeks after ACLT
(ACLT +NS, 9 w), 4) OA knees with normal saline treat-
ment 16 weeks after ACLT (ACLT +NS, 16 w), 5) OA
knees with DHEA treatment 9 weeks after ACLT (ACLT+
DHEA, 9 w) and 6) OA knees with DHEA treatment
16 weeks after ACLT (ACLT +DHEA, 16 w).
Gross observation
After the rabbits were sacrificed, gross morphologic
grading of the four sections (MFC, LFC, MTP and LTP)
was performed separately according to the following
scale: grade 0, smooth surface with normal color; grade
1, rough surface with minimal fibrillation or a slight
yellowish discoloration; grade 2, cartilage erosion ex-
tending into the superficial or middle layers; grade 3,
cartilage ulceration extending into the deep layers; and
grade 4, cartilage depletion with the subchondral bone
exposed [11]. In the current study, cartilage with grade
2–3 changes was recognized as the morphologic features
of middle stage of disease process. Significant cartilage
thinning, subchondral sclerosis, and osteophyte formation
which were corresponding to grade 4 were considered to
be the morphologic features of advanced stage of OA. The
examination was performed by two independent patholo-
gists who were blinded to the treatment groups. The spec-
imens were photographed with a high-resolution digital
camera (PowerShot G12, Canon, Japan).
Histological examinations
The proximal tibia and the distal femur of the oper-
ated knees from each rabbit were fixed in 10 %
neutral-buffered formalin and then placed in 15 %
disodium-ethylenediaminetetraacetic acid (EDTA-2Na).
After decalcification was complete, the surface areas of the
four compartments (i.e., LFC, MFC, LTP and MTP) at risk
for OA lesions were each divided into four 3-mm thick
osteochondral slabs (anterior to posterior for the tibia and
abaxial to axial for the femoral condyle). After routine
histologic processing, each osteochondral slab was embed-
ded in paraffin (anterior surface down for the tibial slabs
and abaxial surface down for the femoral condyle slabs)
and 5-μm sections were stained with Safranin O. The tis-
sue sections obtained from the two central osteochondral
slabs of each four weight-bearing compartments, which
usually shows the earliest and most severe histological ab-
normalities [12] were evaluated using the Mankin’s grad-
ing system by an experienced cartilage pathologist [13](Fig. 1). The observer was blinded for the treatment re-
ceived by the rabbit group source and macroscopic de-
scription of the samples, which were presented in random
order.
Statistical analysis
All data are expressed as the mean ± standard deviation
(SD). Statistical analysis of the gross morphology data was
performed using the nonparametric Mann–Whitney U
test. The histological data were analyzed using a paired t-
test. The statistical analyses were performed with SPSS




All operations were performed without complications. At
euthanasia, no significant variation in the body weights be-
tween the experimental groups was observed and the
complete transection of each ACL was confirmed grossly.
In the current study, at 4 weeks after model establishment,
safranin O staining in the ACLT group was partially lost
and fibroses were observed on the surface of hyaline cartil-
age, indicating loss of articular cartilage proteoglycan and
induction of early OA. The ACLTanimals in placebo group
that were sacrificed at 9 weeks demonstrated histo-
logical features that included extensive partial thickness
fissures, loss of the superficial zone layer and empty
chondrocyte lacunae within the remaining cartilage
with reduced Safranin-O staining, which is similar to
the pathological changes in the middle stage of human
OA. The animals that were sacrificed at 16 weeks had
progressive osteophytosis in the medial knee compart-
ment, as well as partial or full thickness cartilage ero-
sion of the femoral condyle, and to a lesser extent, in
the tibial plateau. In most cases, there was little or no
cartilage remaining in the MFC, leaving the subchon-
dral bone exposed, which corresponded to the patho-
logical changes in the terminal stage of human OA.
Macroscopic grading in the middle and terminal stages
of OA
In the sham operation joints, the macroscopic grades
were 0 (normal). No cartilage erosion was observed in
any joint compartment. The sham group was included
for comparative purposes to demonstrate that the ACLT
surgery we performed induced degenerative changes in
the articular cartilage. The DHEA 9 w group had a lower
severity grade of macroscopic cartilage lesions in the 4
joint compartments compared with that in the NS 9 w
group, and this difference was significant (MFC P = 0.013;
LFC P = 0.048; MTP P = 0.045; LTP P = 0.02). The DHEA
16 w group has a significantly lower severity grade of
macroscopic cartilage lesions in the LFC and LTP
Fig. 1 The medial and lateral tibias as well as the medial and lateral femoral condyles were each divided into four 3 mm-thick osteochondral slabs,
and the central two slabs (*) obtained from each of four major weight-bearing compartments were histologically examined. M: medial. L: lateral
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(LFC P = 0.046; LTP = 0.034); however, the between-group
difference in the macroscopic score for the MFC and
MTP was not significant (P > 0.05). Figure 2 presents the
macroscopic grading in the four regions among the
groups. Figures 3 and 4 display typical macroscopic cartil-
age lesions among the groups in the four regions for the
different OA stages.
Histological observations in the middle and terminal
stages of OA
A quantitative histomorphometric assessment of the sec-
tions stained with Safranin O was performed using theFig. 2 Macroscopic grades of the articular surfaces of the femoral condyles
and LTP). Data are presented as the mean percentage distribution of grade
placebo-treated groupMankin scoring system. Similar to the degeneration
trends in the macroscopic grading, the histological ana-
lyses showed that the lesions increased during middle to
advanced OA. Typically, cartilage erosion with loss of
the superficial or even the mid-zone was observed
9 weeks after ACLT. In the 16th week, microfractures
became visible through the bone plate or the contour of
the articular surface changed because of bone remodel-
ing. Generally, minor lesions could be observed in the
ACLT +DHEA group compared to the ACLT +NS
group at 9 and 16 weeks after ACLT. In the DHEA
groups, rare ulceration and a slight increase in the num-
ber of chondrocyte layers were observed. In addition,and tibial plateaus. Four compartments were graded (MFC, LFC, MTP
s. *P < 0.05 for the DHEA-treated group compared with the
Fig. 3 Typical macroscopic cartilage lesions among the groups in the four regions for the OA middle stage. The DHEA 9 w group exhibited a
lower severity grade of macroscopic cartilage lesions in the 4 joint compartments compared with the NS 9 w group (P < 0.05). a-c represents the
medial femoral condyles (MFC) of different groups (a: Sham, 9 w; b: ACLT+ DHEA, 9 w; c: ACLT + NS, 9 w). d-f represents the lateral femoral
condyles (LFC) of different groups (d: Sham, 9 w; e: ACLT+ DHEA, 9 w; f: ACLT + NS, 9 w). g-i represents the medial tibial plateaus (MTP) of
different groups (g: Sham, 9 w; h: ACLT+ DHEA, 9 w; i: ACLT + NS, 9 w). j-l represents the medial tibial plateaus (LTP) of different groups (j: Sham,
9 w; k: ACLT+ DHEA, 9 w; l: ACLT + NS, 9 w)
Fig. 4 Typical macroscopic cartilage lesions among the groups in the four regions for the advanced stage of OA. The DHEA 16 w group
exhibited significantly lower severity grades of macroscopic cartilage lesions in the LFC and LTP compartments compared with those observed in
the NS 16 w group (P < 0.05); however, the between-group difference in the macroscopic scores for the MFC and MTP were not significant
(P > 0.05). a-c represents the medial femoral condyles (MFC) of different groups (a: Sham, 16 w; b: ACLT+ DHEA, 16 w; c: ACLT + NS, 16 w). d-f
represents the lateral femoral condyles (LFC) of different groups (d: Sham, 16 w; e: ACLT+ DHEA, 16 w; f: ACLT + NS, 16 w). g-i represents the
medial tibial plateaus (MTP) of different groups (g: Sham, 16 w; h: ACLT+ DHEA, 16 w; i: ACLT + NS, 16 w). j-l represents the medial tibial plateaus
(LTP) of different groups (j: Sham, 16 w; k: ACLT+ DHEA, 16 w; l: ACLT + NS, 16 w)
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pared to those in the placebo groups. In the middle and
advanced stages of OA, the cartilage was thicker in the
DHEA groups than in the placebo groups. The distribu-
tion of chondrocytes in the areas with OA lesions was
normal or slightly hypercellular in the DHEA groups, in-
dicating regenerative activity; in the placebo groups,
hypocellularity or aggregation of the chondrocytes was
observed. Safranin-O staining, which could specifically
bind to the proteoglycan in the ECM, was positive in the
majority of the DHEA group specimens and in a minority
of the placebo group specimens. The total Mankin scores
of four regions were significantly higher in ACLT +NS
group compared with those in ACLT +DHEA group at
9 weeks (MFC P = 0.012; LFC P = 0.034; MTP P = 0.016;
LTP P = 0.002). The total Mankin scores of LFC and LTPFig. 5 Representative Safranin O/fast green-stained histologic sections illus
groups in the four regions for the middle stage of OA. All DHEA-treated gr
the 4 joint compartments compared with placebo-treated groups with the
compartments were observed between the DHEA 16 w and NS 16 w grou
DHEA, 9w; d: LFC ACLT + NS, 9 w; e: MTP ACLT+ DHEA, 9w; f: MTP ACLT +
histological changes among the groups in the four regions for the advance
LFC ACLT+ DHEA, 16 w; l: LFC ACLT + NS, 16 w; m: MTP ACLT+ DHEA, 16 w
NS, 16 w). (Original magnification ×200, scale bar 50 μm)in ACLT +NS group at 16 weeks is significantly higher
than those in ACLT +DHEA group (LFC P = 0.005; LTP
P = 0.002), while no statistically significant differences in
the total Mankin scores for the MTP and MFC compart-
ments were observed between the ACLT +DHEA 16 w
and ACLT +NS 16 w groups which was consistent with
the macroscopic data. The above data indicate that DHEA
exerts an anabolic effect on cartilage by stimulating the
synthesis of the cartilage matrix components and by in-
creasing the proteoglycan synthesis mainly in the middle
stage of OA. Figure 4 shows the quantitative histological
results of the articular cartilage during the development of
OA. Figure 5 shows typical sections of cartilage in differ-
ent groups during both stages of OA. Figure 6 presents
the histological score for articular cartilage of various
groups 9 weeks after operation. Figure 7 presents thetrating cartilage lesions. a-h represents histological changes among the
oups exhibited lower severity grades for histological cartilage lesions in
exception that no histological differences for the MTP and MFC
ps. (a: MFC ACLT+ DHEA, 9w; b: MFC ACLT + NS, 9 w; c: LFC ACLT+
NS, 9 w; g: LTP ACLT+ DHEA, 9w; h: LTP ACLT + NS, 9 w). i-p represents
d stage of OA (i: MFC ACLT+ DHEA, 16 w; j: MFC ACLT + NS, 16 w; k:
; n: MTP ACLT + NS, 16 w; o: LTP ACLT+ DHEA, 16 w; p: LTP ACLT +
Fig. 6 Histologic scores of the articular surfaces of the femoral condyles and tibial plateaus 9 weeks after operation. The scores for the histologic
parameters with between-group comparisons are presented. Values represent the mean and SD. Histologic analysis revealed that the total Mankin
score of DHEA-treated groups was significantly reduced compared with that of placebo-treated groups in both compartments of the knee. *P < 0.05
for the DHEA-treated group compared with the placebo-treated group. **P < 0.01 for the DHEA-treated group compared with the
placebo-treated group
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16 weeks after operation.
Discussion
OA is one of the leading causes of disability worldwide and
is a serious burden to patients and society. Although the
pathogenesis of OA is not fully understood, a central hall-
mark in this slow, chronic disease is progressive destruction
of the articular cartilage. Thus, ideal medication should be
able to retard this process and positively impact different
aspects of the disease, including structural and metabolic
changes in the joint components. DHEA appears to fulfill
many of these requested criteria, such as having no toxic ef-
fects on the chondrocytes [9], possessing anti-inflammatory
properties [14], and antagonizing the catabolic mediators
and anabolic effects on the cartilage matrix [15].
The initial study by Williams et al. [16] reported that re-
peated administration of DHEA during arthritis inductiondelayed the onset and decreased the severity of collagen-
induced arthritis in male and female DBA/1 mice. In a re-
cent study, Jo et al. [17] showed that treating chondrocytes
isolated from human osteoarthritic knee cartilage with
DHEA significantly suppressed the gene expression and
protein synthesis of MMP-1, while increasing the gene ex-
pression and protein synthesis of TIMP-1. Based on these
studies, similar results in our previous work showed that
DHEA protects against joint destruction and inhibits the
progression of OA by modulating the catabolic/anabolic
balance of cartilage, including the MMPs/TIMP-1 system
[18] and the ADAMTS/TIMP-3 system [10, 19].
The aforementioned studies predominantly focus on the
protective role of DHEA on cartilage at the molecular
level. There is insufficient data demonstrating a potentially
beneficial role of DHEA in the pathological changes that
occur in OA. To provide a histological explanation for pre-
vious molecular results, this study focused on evaluating
Fig. 7 Histologic scores of the articular surfaces of the femoral condyles and tibial plateaus 16 weeks after operation. DHEA treatment reduced
the total Mankin score in the lateral compartment. However, the total Mankin score of the medial compartment between groups does not have
significant differenence. *P < 0.05 for the DHEA-treated group compared with the placebo-treated group. **P < 0.01 for the DHEA-treated group
compared with the placebo-treated group
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joint compartments during the stages of OA after adminis-
tering DHEA. The macroscopic and histological findings of
this study matched well with the evidence provided in the
above molecular experiments, indicating a chondroprotec-
tive role of DHEA in a surgically induced OA model.
The current data showed that the histological changes
are time-dependent and site-specific; the cartilage lesion
after ACLT showed increasing severity with the develop-
ment of the disease and was similar to that in a clinical
situation. In addition, the lesions in the medial femoroti-
bial compartment presented earlier and were more ad-
vanced than those in the lateral compartment, likely
because the medial compartment is the primary weight-
loading region of the knee, thus the cartilage might de-
generate faster than in other sections of the joint.
The Mankin analyses revealed that the DHEA injections
effectively inhibited the progression of existing cartilage
degeneration in both knee compartments at 9 weekspostoperatively and in the lateral knee compartment at 16
postoperative weeks. The Safranin O staining showed that
the loss of proteoglycan could be prevented by DHEA ad-
ministration, which is consistent with a relevant in vitro
study reporting that DHEA could stimulate articular car-
tilage integration (reflected by increased glycosaminogly-
can content) [20]. However, no effects were detected at 16
postoperative weeks in the MFC and MTP of the joint.
This finding indicates that DHEA administration does not
greatly affect the medial compartment, which endures the
most stress force when OA develops into the advanced
stage. We hypothesize that DHEA most likely plays a
beneficial role when the cartilage matrix remains during
disease progression, such as in the early and middle stages
of OA. In the terminal stage of OA, full thickness cartilage
damage occurs, leaving the subchondral bone exposed,
particularly in the MFC and MTP, which causes the matrix
restoration process conducted by the chondrocytes to be
unresponsive to DHEA stimulation. Another explanation
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generation process markedly exceeds the cartilage matrix
recovery process induced by DHEA, leading to severe car-
tilage damage similar to that in the control group. Thus,
the between-group difference in the cartilage quality in the
medial compartment is not significant. We also found that
the Mankin score of the lateral compartment of placebo
group in terminal OA is significantly lower than that of
medial compartment (data not shown). Based on the above
two hypotheses, it is reasonable to explain why DHEA still
work on the lateral compartment at advanced stage of OA.
Many studies have revealed the important role of the
Wnt/β-catenin signaling pathway in the pathogenesis of
OA [21–23]. Dell'accio and his colleagues [24] also dem-
onstrated that Wnt/β-catenin proteins are up-regulated in
joint areas with moderate-to-severe OA damage. Consist-
ent with Dell'accio’s study, Lories et al. [25] also reported
that cartilage loss is associated with a trend towards in-
creased β-catenin levels in damaged cartilage in a mice
model of OA. The results of the two studies suggest that
Wnt/β-catenin signaling activation is enhanced in ad-
vanced OA with severe joint damage compared with the
early and middle stages of the disease. Moreover, our most
recent study [26] demonstrated that DHEA likely exerts
its anti-osteoarthritic effect by regulating Wnt/β-catenin
signaling. The protective effect of DHEA was significantly
decreased when Wnt/β-catenin signaling was activated,
whereas the inactivation of Wnt/β-catenin signaling en-
hanced the effects of DHEA. Thus, the third explanation
demonstrates why DHEA administration does not greatly
affect the medial compartment in the present research; in
this region, the cartilage exhibited the most severe dam-
age, and the activation of Wnt/β-catenin signaling is up-
regulated.
Now osteoarthritis is viewed as a multifactorial disease
affecting the whole joint. Although previous research fo-
cused primarily on changes in the articular cartilage,
more recent studies have highlighted the importance of
the subchondral bone, menisci, ligaments, synovium and
periarticular muscles [27, 28]. Thus, a limitation of this
study is that apart from articular cartilage we have not
examined any effects of DHEA on other joint tissues like
subchondral bone and menisci due to the limited joint
specimen.
Conclusion
Intra-articular DHEA injection plays a chondroprotec-
tive role in both compartments of the knee in the middle
stage of OA, whereas DHEA was chondroprotective only
in the lateral compartment in advanced OA. The disease-
modifying efficacy of DHEA aganist OA is time-specific
and site-dependent. DHEA could be used as a disease-
modifying strategy to limit the progression of OA, espe-
cially in the middle stage.Abbreviations
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